Attention training technique delivered in groups as treatment for anxiety and depression in patients with coronary heart disease: study protocol for a waiting-list randomized controlled trial

Frontiers in Psychology

Psychology

John Munkhaugen¹  Costas Papageorgiou²  Ole Klungsøyr³  Toril Dammen³  Kristoffer Tunheim⁴ 

[1] Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway;Department of Behavioural Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway;Department of Psychology, University of Oslo, Oslo, Norway;Department of Research and Innovation, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway;Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway;Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway;Department of Medicine, Drammen Hospital, Vestre Viken Trust, Drammen, Norway;

关键词: attention training technique;    anxiety;    depression;    rumination;    worry;    psychological intervention;    coronary heart disease;   

DOI  :  10.3389/fpsyg.2023.1226539

 received in 2023-05-21, accepted in 2023-08-30,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionClinically significant symptoms of depression and anxiety in coronary heart disease (CHD) patients are common and associated with adverse outcomes. Psychological treatments have shown limited effectiveness and more effective treatments have been requested. Attention training technique (ATT), a component of metacognitive therapy, can potentially be effective as a stand-alone treatment for anxiety and depression. In an open study, ATT delivered face-to-face in a group format was feasible and potentially effective for improving depression and anxiety symptoms in CHD patients. The next progressive step is to test the effectiveness of ATT in a randomized controlled trial. This paper describes the methodology of this trial.MethodsATT-CHD is a randomized wait-list (WL) controlled study. Eligible CHD patients from two hospitals with Hospital Anxiety and Depression Scale (HADS)-Anxiety and/or HADS-Depression subscales scores ≥8 will be randomized into ATT (n = 32) or WL control (n = 32). After 6–8 weeks, WL patients will be allocated to ATT. Participants will be evaluated pre-, mid- and post-treatment, and at 6-months follow-up using changes in HADS as primary outcome. Secondary outcomes will be changes in psychiatric disorders, rumination, worry, type D-personality, metacognitions, insomnia, quality of life, and C-Reactive protein (CRP).DiscussionTo our knowledge, this will be the first WL-controlled randomized study testing the effectiveness of group-based ATT as treatment of symptoms of anxiety and depression in CHD patients. It will also explore correlations between changes in psychological distress and CRP. A qualitative analysis will reveal patients’ experience with ATT including processes that may facilitate or serve as barriers to effectiveness. Recruitment into the study commenced in December 2022.Ethics and disseminationThe Regional Committees for Medical and Health Research Ethics (REK), Norway has granted approval for the study (ID 52002). The trial results will be published in peer-reviewed journals. According to Norwegian legislation, the Norwegian Data Protection Authority, and the Committee of Ethics, we are not allowed to share original study data publicly.Clinical trial registrationClinicalTrials.gov, identifier NCT05621408 pre-inclusion. There were no significant changes of methods or outcomes after study start.

【 授权许可】

Unknown   
Copyright © 2023 Dammen, Tunheim, Munkhaugen, Klungsøyr and Papageorgiou.

【 图 表 】

fonc-13-1241532-i002.tif

fpsyg-14-1226539-i001.tif

fmicb-14-1258415-i071.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fmicb-14-1258415-i058.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fimmu-14-1264383-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fimmu-14-1236332-i007.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fimmu-14-1236332-i005.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fphar-14-1211452-fx9.tif

fanim-04-1259200-i005.tif

fnagi-15-1217746-i010.jpg

fnagi-15-1217746-i008.jpg

fcvm-10-1160201-i002.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fonc-13-1244628-i001.tif

FENVS_fenvs-2023-1175239_wc_tfx3.tif

FENVS_fenvs-2023-1175239_wc_tfx2.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fpsyg-14-1226539-i001.tif

fmicb-14-1258415-i014.tif